Stem cells

Female scientist looking through microscope
#Human disease models #Humanised Immune System (HIS) #Stem cells #The Jackson Laboratory

Which immune-humanized platform is best for your application?

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Axol Bioscience #Neuroscience #Stem cells #StrataStem

A step closer to ‘clinical trial in a dish’ for Alzheimer’s  

Axol Bioscience has signed an exclusive agreement with StrataStem to access and commercialise its collection of Alzheimer’s Disease (AD) patient samples.   Harnessing its stem cell expertise, Axol will reprogramme these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a range… Read More

#News

Laboratory equipment
#Human disease models #Humanised Immune System (HIS) #Stem cells #The Jackson Laboratory

Which immune-humanized platform is best for my application?

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

Laboratory equipment
#Human disease models #Humanised Immune System (HIS) #Stem cells #The Jackson Laboratory

Comparing immune-humanized platforms: Which one is best for my application?

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate immune function. Read More

Webinar date:
Brought to you by The Jackson Laboratory
#Webinars

Stem cells
#Regulatory #Stem cells #Universiti Sains Malaysia #University of Reading

Scientists call for tighter regulation of stem cell treatments

Scientists are calling for tighter regulation of stem cell treatments, claiming clinics worldwide are offering unproven ‘therapies’ for conditions as varied as hair loss and Parkinson’s. Researchers at the University of Reading and the Universiti Sains Malaysia have identified 114 companies in over 20 countries offering unproven, unregulated, stem-cell derived… Read More

#Editor's Choice #News #Regulatory

CRISPR gene editing
#CRISPR #Gene editing #Genetics / genomics #Stem cells

New research begins to write the rules on CRISPR activation

UK researchers, from the Wellcome Sanger Institute and collaborators, have used human stem cells and neurons to investigate what features influence how well CRISPR activation works for different sets of genes. Published in Molecular Cell, the study explains the rules determining to what extent genes respond… Read More

#News

Genetic engineering
#Cell and gene therapy #CNS #Gene editing #Gene therapy #Genetics / genomics #Paediatrics #Stem cells

Gene therapy for ‘childhood dementia’ shows promise

An investigational gene therapy for Sanfilippo syndrome – which leads to a form of childhood dementia – has shown promising early results in a proof-of-concept study.  The study found that four out of five patients diagnosed with Sanfilippo have continued to gain cognitive skills in line with… Read More

#Editor's Choice #News

#Biopharma #Cell and gene therapy #Drug discovery #Stem cells

The use of base editing in stem cell-based therapies

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies.   Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential… Read More

#Exclusive Content

Patient with dry eye disease using eye drops
#Dry eye #FDA #Ophthalmology #Phase III trial #Stem cells

Stem cell dry eye therapy could offer rapid and total relief

The US Food and Drug Administration (FDA) has approved the Phase III clinical trial design for BRIM Biotechnology’s lead candidate for dry eye disease (DED), BRM421. BRIM will submit the Phase III study protocol to the FDA later this year.  BRM421 is a novel, first-in-class regenerative peptide therapy which, if… Read More

#News #Regulatory

Stem cell research
#Blood cell production #Immunity #Investment #Stem cell rejuvenation #Stem cells

Stem cell rejuvenation startup secures investment 

Biotech company Mogling Bio has successfully has completed its first seed investment round with a sole investor, Kizoo Technology Capital.  Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.   Ageing causes stem cells to lose their normal structure by increased… Read More

#Business & Investment #News

#Drug discovery #Spinal cord injury #Stem cells

Latent stem cells could repair spinal cord damage

A group of latent stem cells could be the key to developing new therapeutic approaches to treat brain and spinal cord injuries, research shows. Scientists at the Francis Crick Institute identified a group of latent stem cells in mice which respond to injury in the central nervous system. If the… Read More

#News

#AI #Chronic pain #Finance #Funding #Start-ups #Stem cells

International start-ups receive funding from BioInnovation 

Three international life sciences start-ups have received investment from the BioInnovation Institute (BII).   The three new ventures were chosen as part of the BII’s focus on developing scientific initiatives across the therapeutics and health tech space.  The companies, Sevenless Therapeutics, VEIL.AI and Myopax, will receive €1.3 million and will form… Read More

#Business & Investment #News

#Assay #Stem cells

Axol Bioscience introduces stem cells for cardiotoxicity  

Life sciences provider Axol Bioscience has announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. By using this assay, Axol was able to show that the cells were suitable for measuring cardiotoxicity, offering scientists a robust cardiac… Read More

#News

#Mouse models #Stem cells

Lonza expands to enable efficient humanised mouse model development

Lonza has expanded its human stem cell offerings to provide human cord blood CD34+ haematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a rapidly expanding market need.  CB-CD34+ HSCs are the preferred cell choice for creating humanised mouse models, which are critical for preclinical… Read More

#News

Stem cells
#Biologics / Biotechnology #Immunology / Virology & Vaccines #Stem cells

Podcast: Is customisation healthcare’s secret weapon? 

This is the latest episode of the free DDW podcast, “Is customisation healthcare’s secret weapon?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW.  The articles are called “Optimising vaccine production through customisation” and “Exploring iPSCs for individual… Read More

#News